Poly(ethylene glycol) Transport Forms of Vancomycin: A Long-Lived Continuous Release Delivery System

Journal of Medicinal Chemistry

Volumn 46, Issue 23, 2003, Pages 5021-5030

  Greenwald, Richard B ^a   Zhao, Hong ^a   Xia, Jing ^a   Martinez, Anthony ^a  

^a Enzon Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG TRANSPORT; MOUSE; NONHUMAN; RAT; STAPHYLOCOCCUS INFECTION; SURVIVAL;

EID: 0242362582     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030202g     Document Type: Article

References (23)

1. Kirby, W. M. M. Vancomycin therapy in severe staphyloccal infections. Rev. Infect. Dis. 1981, 3, 5236-5239.
2. Ingerman, M. J.; Santoro, J. Vancomycin a new old agent. Infect. Dis. Clin. North Am. 1989, 3, 641-651.
3. Pryka, R. D.; Rodveld, K. A.; Erdman, S. M. An updated comparison of drug dosing methods. IV. Vancomycin. Clin. Pharmacokinet. 1991, 20, 463-476.
4. James, J. K.; Palmer, S. M.; Levine, D. P.; Rybac, M. J. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob. Agents and Chemother. 1996, 40, 696-700.
5. Klepser, M. E.; Patel, K. B.; Nicolau, D. P.; Quintiliani, R.; Nightingale, C. H. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy 1998, 18, 1069-1074.
6. Wysocki, M. et al. Continuous versus intermittent infusion of vancomycin in severe Staphyloccal infections: Prospective multicenter randomized study. Antimicrob. Agents Chemother. 2001, 45, 2460-2467.
7. Sinkula, S. S.; Yalkowsky, S. H. Rationale for design of biologically reversible drug derivatives: Prodrugs. J. Pharm. Sci. 1975, 64, 181-210.
8. Pavlov, A. Y. Preobrazhenskaya. Chemical modification of glycopeptide antibiotics [VC1]. Russian J. Bioorg. Chem. (Eng. Version). 1998, 24, 570-587.
9. Nagarajan, R.; Schabel, A. A.; Occolowitz, J. L.; Counter, F. T.; Ott, J. L. Synthesis and antibacterial activity of N-acyl vancomycins. J. Antibiot. 1988, XLI, 1430-1438.
10. Schecter, Y.; Tsubery, H.; Fridkin, M. J Med. Chem. 2002, 45, 4264-4270.
11. Pang, S. J. Final report on the safety assessment of poly(ethylene glycol) (PEGs). J. Am. College Toxicol. 1993, 12, 429.
12. Kannan, R.; Harris, C. M.; Harris, T. M.; Waltho, J. P.; Skelton, N. J.; Williams, D. H. Function of the amino sugar and N-terminal amino acid of the antibiotic vancomycin in its complexation with cell wall peptides. J. Am. Chem. Soc. 1988, 110, 2946-2953.
13. Perkins, H. R. Specificity of combination between mucopeptide precursors and vancomycin or ristocetin. Biochem. J. 1969, 111, 195-205.
14. Adamczyk, M.; Grote, J.; Moore, J. A.; Rege, S. D.; Yu, Z. Structure-binding relationships for the interaction between a vancomycin monoclonal antibody fab fragment and a library of vancomycin analogues and tracers. Bioconjugate Chem. 1999, 10, 176-185.
15. Ghosh, M.; Miller, M. J. Synthesis and in vitro antibacterial activity of spermidine-based amixed catechol- and hydroxamate-containing siderophore-vancomycin conjugates. Bioorg. Med. Chem. 1996, 4, 43-48.
16. Staroske, T.; Williams, D. H. Synthesis of covalent head-to-tail dimers of vancomycin. Tetrahedron Lett. 1998, 39, 4917-4920.
17. Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: Soluble taxol 2′-poly (ethylene glycol) ester progroup - design and in vitro effectiveness. J. Med. Chem. 1996, 39, 424-431.
18. Greenwald, R. B.; Pendri, A.; Conover, C. D.; Zhao, H.; Choe, Y. H.; Martinez, A.; Shum, K.; Guan, S. Drug delivery systems employing 1,4-or 1,6-elimination: poly (ethylene glycol) prodrugs of amine containing compounds. J. Med. Chem. 1999, 42, 3657-3667.
19. Greenwald, R. B.; Yang, Y.; Zhao, H.; Conover, C. D.; Lee, S.; Filpula, D. Controlled release of proteins from their poly-(ethylene glycol) conjugates: Drug delivery systems employing 1,6-elimination. Bioconjugate Chem. 2003, 14, 395-403.
20. Lee, S.; Greenwald, R. B.; McGuire, J.; Yang, K.; Shi, C. Drug delivery systems employing 1,6-elimination: releasable poly-(ethylene glycol) conjugates of proteins. Bioconjugate Chem. 2001, 12, 163-169.
21. 4-acyl poly (ethylene glycol) prodrugs of ara-C. I. Efficacy in solid tumors. J. Controlled Release 2000, 79, 41-53.
22. 4-acyl poly (ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J. Controlled Release 2000, 79, 55-70.
23. Yamaoka, T.; Tabata, Y.; Ikada, Y. Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 1994, 83, 601-606.